Participants from private, public, and government sectors discuss the future of ophthalmic drug development.
Medscape Medical News
Daily Archives: 2011/11/22
Poor folate status predicts persistent diarrhea in 6- to 30.month old north Indian children
By: mariskarmanger
Bionic Contact Lens to Check Your Email
We’re another step closer to integrating real time information into our vision. Researchers from the University of Washington and Aalto University Finland have engineered the first prototype of a computerized contact lens on which you can see information updates. They presented their findings today in IOP Publishing’s Journal of Micromechanic (Read more...)
Calling Doctor Nurse!
Physicians discuss whether nurses and physician assistants should be addressed as "doctor" by patients.
Medscape Family Medicine
Medscape Family Medicine
EYLEA (aflibercept): New Treatment for Wet ARMD Approved!
 |
On Friday (11/20), the FDA approved Eylea for the treatment of wet macular degeneration. Eylea is another anti-VEGF based treatment designed for intraocular injection.
Eylea has several names. Eylea is also known as VEGF Trap-Eye. The generic name is aflibercept.
Eylea = VEGF Trap-Eye = aflibercept
VEGF Trap-Eye Works With Fewer Injections
Several pivotal studies suggest Eylea and Lucentis to be equally ef (Read more...)
Failure of Super Committee Blows Doc-Fix Opportunity
The impact of the committee's failure on physicians is 2-fold: a missed opportunity to repeal Medicare’s sustainable growth rate formula and a 2% pay cut for Medicare providers in 2013.
Medscape Medical News
Medscape Medical News
Regeneron’s Eylea for treating age related macular degeneration gets FDA nod
Regeneron Pharmaceuticals has received marketing approval for their eye drug - Eylea, an injection meant to treat a common cause of blindness in older people. Eylea can be used to treat “wet” age-related macular degeneration. The only other drug approved for the condition is Lucentis from Roche, which was approved in 2006.
Subscribe
